Results 261 to 270 of about 405,156 (331)

The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis - Worldwide, 2016-2025. [PDF]

China CDC Wkly
Chen Q, Yin W, Zhu Z, Wang C.
europepmc   +1 more source

Flow‐Induced Vascular Remodeling on‐Chip: Implications for Anti‐VEGF Therapy

Advanced Functional Materials, Volume 35, Issue 42, October 15, 2025.
Flow‐induced vascular remodeling plays a critical role in network stabilization and function. Using a vasculature‐on‐chip system, this study reveals how physiological VEGF levels and flow affect vascular remodeling and provides insights into tumor vessel normalization.
Fatemeh Mirzapour‐Shafiyi, Elias Huber, Leonie Karr, Johnny Tong, Andreas Richard Bausch, Friedrich Christian Simmel, Karen Alim   +6 more
wiley   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Reprogramming of Fatty Acid Metabolism via PPARα‐Orchestrated FADS2 in Keratinocytes Modulates Skin Inflammation in Psoriasis

Advanced Science, Volume 12, Issue 40, October 27, 2025.
This study identifies fatty acid desaturase 2 (FADS2) as a key regulator linking polyunsaturated fatty acid (PUFA) metabolism to psoriatic inflammation. FADS2 deficiency impairs docosahexaenoic acid (DHA) biosynthesis, enhances NF‐κB signaling, and promotes neutrophil‐driven skin inflammation. PPARα transcriptionally activates FADS2, and its activation
Jiangluyi Cai, Xue Zhou, Yu Zhuang, Lian Cui, Rui Ma, Youdong Chen, Nan Yang, Qianyu Chen, Yuanyuan Wang, Peiyao Zhu, Lingling Yao, Qian Yu, Xiaomin She, Xuyang Zhou, Yuemeng Huang, Zengyang Yu, Xilin Zhang, Jiajing Lu, Yuling Shi, Chunyuan Guo   +19 more
wiley   +1 more source

Circulating Antibody's Role During Post-Exposure Prophylaxis, and Beyond for Rabies: A Review. [PDF]

Vaccines (Basel)
Chen Q, Cai L, Lv X, Liu S, Liu C, Liu J, Liu X, Yin W, Wang C, Zhu Z.   +9 more
europepmc   +1 more source

Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity

Advanced Science, Volume 12, Issue 37, October 6, 2025.
The co‐delivery of mRNAs encoding a CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21) via lipid nanoparticles enables effective localized immunotherapy. This strategy not only suppresses tumor progression but also enhances type 1 conventional dendritic cell (cDC1) differentiation and activates CD8+ T cells, thereby inducing robust ...
Tao Jiang, Shuaiyang Jing, Haojun Li, Bao Xiao, Jiahui Jin, Xiu Sun, Juan Wang, Jing Liang, Tongze Cai, Huili Hu, Meilan Wei, Xuanrui Zhong, Yang Ji, Peng George Wang, Jianlong Zhou   +14 more
wiley   +1 more source

Strengthening RSV prevention in early life through new generation strategies. [PDF]

J Pediatr (Rio J)
Mejias A, Ramilo O.
europepmc   +1 more source

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

Advanced Science, Volume 12, Issue 39, October 20, 2025.
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz, Jessica Cutrufello, Michael Lam, Shreya Nallaparaju, Nicholas A. Peppas   +4 more
wiley   +1 more source

Application of nanobody‑based CAR‑T in tumor immunotherapy (Review). [PDF]

Int J Mol Med
Liu H, Liu X, Zhou X, Duan S, Huang X, Fei H, Kou Y.   +6 more
europepmc   +1 more source

RESP2: An Uncertainty Aware Multi‐Target Multi‐Property Optimization AI Pipeline for Antibody Discovery

Advanced Science, Volume 12, Issue 38, October 13, 2025.
RESP2, an enhanced antibody discovery pipeline for multi‐target and multi‐property optimization, identifies antibodies with optimized developability and broad affinity to multiple antigen variants. In silico evaluation shows RESP2 outperforms leading AI methods, achieving ≥85% success rates.
Jonathan Parkinson, Ryan Hard, Young Su Ko, Wei Wang   +3 more
wiley   +1 more source